论文部分内容阅读
目的:分析低氧诱导因子-2α(HIF-2α)在肝细胞癌组织中的表达,探讨其与肝细胞癌临床病理特征的相关性及临床意义。方法:收集天津医科大学附属肿瘤医院104例经手术治疗并有完整随访资料的肝细胞癌和10例正常肝组织标本,用免疫组化方法观察HIF-2α和CD34在癌组织中的表达情况,分析HIF-2α表达水平与肝细胞癌微血管密度、临床病理特征及患者预后的关系。结果:正常肝组织无HlF-2α表达,104例患者中HIF-2α蛋白表达(-)32例,(+)32例,(++)40例;HIF-2α表达与肝细胞癌的分化程度、TNM分期及伴发肝硬化呈正相关关系(P<0.05);HIF-2α蛋白较高表达组MVD显著高于HIF-2α蛋白较低表达组(P<0.05);HIF-2α高表达患者组的3年生存率低于低表达患者组(12.8%vs 60.8%,P<0.001)。经Cox多因素回归分析,HIF-2α是肝细胞癌的独立预后因素(P<0.001)。结论:HIF-2α的阳性表达与肝细胞癌血管新生、病理分级、TNM分期及总生存率密切相关;提示HIF-2α可作为评估肝细胞癌进展及预后的指标之一。
OBJECTIVE: To analyze the expression of hypoxia inducible factor-2α (HIF-2α) in hepatocellular carcinoma (HCC) and to investigate the relationship between the expression of HIF-2α and the clinicopathological features of HCC. Methods: Totally 104 cases of hepatocellular carcinoma and 10 normal liver tissues surgically treated with complete follow-up data were collected from the Affiliated Tumor Hospital of Tianjin Medical University. The expression of HIF-2α and CD34 in cancer tissues was observed by immunohistochemistry. The relationship between the expression of HIF-2α and the microvessel density, clinicopathological characteristics and prognosis of hepatocellular carcinoma was analyzed. Results: There was no expression of HlF-2α in normal liver tissue, 32 cases of HIF-2α protein (-) in 32 cases, 32 cases of (+) and 40 cases of (++) in 104 cases. The expression of HIF- (P <0.05). The MVD of high HIF-2α protein expression group was significantly higher than that of the low HIF-2α protein expression group (P <0.05); The expression of HIF-2α in high expression group 3-year survival rate was lower in patients with low expression (12.8% vs 60.8%, P <0.001). Cox regression analysis showed that HIF-2α was an independent prognostic factor for hepatocellular carcinoma (P <0.001). Conclusion: The positive expression of HIF-2α is closely related to the angiogenesis, pathological grade, TNM stage and overall survival rate of hepatocellular carcinoma. It suggests that HIF-2α may be used as an index to evaluate the progress and prognosis of hepatocellular carcinoma.